Ties on the overall leaderboard for Online Qualifier will be broken by awarding the best position to the athlete who has the highest result in any single Online Qualifier workout. If athletes remain tied after this first tiebreaker, the process continues to their next-highest single result, and so forth. Results from individual Open workouts will NOT be used to break ties on the overall Online Qualifier leaderboard. Ties will not be broken for single event results. More than one athlete can share an event result, and each will earn the original point value.

The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”
×